USFDA accepts AstraZeneca’s BLA for nirsevimab to prevent RSV lower respiratory tract disease
Nirsevimab is being developed and commercialised by AstraZeneca in collaboration with Sanofi, and is the first single-dose…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
nirsevimab
Sanofi and AstraZeneca win EU approval for prevention of infant RSV
The long-acting therapy, also known as nirsevimab, was given the European Union (EU) marketing authorisation for the prevention of…
Nirsevimab gets Promising Innovative Medicine Designation from MHRA
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…